Vitamin D3 (Cholecalciferol) supplement to enhance the immune status after vaccine against SARS-CoV2, A randomized, double-blind, placebo-controlled trial

Phase 2

• Conditions: Healthy population; SAR-COV2 vaccine, Immunization, Vitamin D supplement

• Registration Number: TCTR20220804008
• Lead Sponsor: Phramongkutklao Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-08-04
• Study Completion: 2022-12-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Healthy volunteers

Exclusion Criteria

1.vitamin D supplement allergy
2.Pregnancy and lactation
3.Previous vitamin D supplement
4.Receiving immunosuppressive therapy
5.Comorbidities : Heart/Kidney/Liver disease, autoimmune disease, malignancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IgG antibody to Spike protein and serum neutralizing antibody At week 4 ELISA

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A